Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Ascletis Pharma Initiates US Phase 1 Study of ASC36 Oral Tablets – An Oral Amylin Receptor Agonist for Obesity, Advancing a Dual‑Format Program Alongside Its Once‑Monthly Injectable

Fineline Cube Sep 9, 2026
Company Drug

Guangzhou Baiyunshan Pharma Wins Registration and Marketing Approval in Macau for Its Freeze‑Dried Rabies Vaccine (Vero Cells) – Joining a Highly Concentrated Supplier Landscape

Fineline Cube Sep 9, 2026
Company Medical Device

Grand Pharma Completes First Atrial Fibrillation Treatment with HeartLight X3

Fineline Cube Feb 15, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the successful completion of the first...

Company Drug

Zelgen’s ZG2001 and ZG0895 Clinical Trials Approved by NMPA

Fineline Cube Feb 15, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that separate clinical trial filings for...

Company Drug

Innovent Biologics Initiates Phase II Study for IBI311 in Thyroid-Associated Ophthalmopathy

Fineline Cube Feb 15, 2023

China-based Innovent Biologics Inc., (HKG: 1801) has announced the first patient dosing in a Phase...

Company Deals

Hygea Medtech Secures Series D Funding for Oncology Device Expansion

Fineline Cube Feb 15, 2023

Hygea Medical Technology Co., Ltd, a leading minimally invasive device maker for oncology indications based...

Company Deals

CTI Acquires Vectoring Pharmatech to Expand Pharmacy CMC Research

Fineline Cube Feb 15, 2023

China-based Centre Testing International Group Co., Ltd (CTI), a leading third-party testing and qualification services...

Company Deals

Shenzhen United Family Hospital Partners with GBA Medical Delegation

Fineline Cube Feb 15, 2023

Shenzhen United Family Hospital has struck a partnership with a medical delegation from the Guangdong-Hong...

Company Deals

Vincentage Raises RMB 100 Million for Innovative Drug Development

Fineline Cube Feb 15, 2023

Suzhou-based new drug developer Vincentage has reportedly raised close to RMB 100 million (USD 14.6...

Company Deals

Sequanta and Grandomics Collaborate on Ultra-High Throughput Sequencing Lab

Fineline Cube Feb 15, 2023

Sequanta Technologies, a multi-omics research and clinical service provider based in Shanghai, and Grandomics Biosciences...

Company Deals

Luzhu Biotech Files for IPO in Hong Kong, Sponsored by CICC

Fineline Cube Feb 15, 2023

Beijing Luzhu Biotechnology Co., Ltd, a leading human vaccine and therapeutic biologics maker, has made...

Policy / Regulatory

China’s NRDL Update: New Drugs Available for Online Procurement

Fineline Cube Feb 15, 2023

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) drug procurement platform has released a notice stating that...

Company Medical Device

Mindray Launches First Wireless Handheld Ultrasound System, TE Air

Fineline Cube Feb 15, 2023

China-based medical device firm Mindray (SHE: 300760) has announced the market launch of the firm’s...

Company Deals

Harbour BioMed Licenses HBM7008 to Cullinan Oncology for US Development

Fineline Cube Feb 14, 2023

Harbour BioMed (HBM), which operates out of the Netherlands, the United States, and Suzhou, China,...

Company Drug

Kangtai Biological Begins Phase I Trial for Tetravalent Influenza Vaccine

Fineline Cube Feb 14, 2023

China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the first subject enrollment...

Company Drug

Jiangsu Recbio Completes First Tranche Enrollment for Shingles Vaccine REC610

Fineline Cube Feb 14, 2023

China-based Jiangsu Recbio Technology Co., Ltd has announced the completion of the first tranche of...

Company Drug

Beijing Wantai Initiates Phase I Study for 20-Valent Pneumonia Vaccine

Fineline Cube Feb 14, 2023

China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) has announced the initiation and...

Company Drug

Gracell Biotechnologies Gains IND Approval for GC012F in China

Fineline Cube Feb 14, 2023

Gracell Biotechnologies has reported receiving Investigational New Drug (IND) approval from the Center for Drug...

Hospital Policy / Regulatory

China’s Ministries Release Plan for Urban Medical Group Pilots

Fineline Cube Feb 14, 2023

A group of ministries led by the National Health Commission (NHC), including the National Development...

Company Deals Digital

ThinmedTech Partners with West China Hospital for CKD Digital Therapy

Fineline Cube Feb 14, 2023

ThinmedTech, a chronic disease clinical management solution provider based in Chongqing, has struck a partnership...

Company Drug

RemeGen Gains NMPA Approval for RC48 and Pyrotinib Clinical Study

Fineline Cube Feb 14, 2023

China-based RemeGen Ltd (HKG: 9995) has announced receiving the go-ahead from the National Medical Products...

Company Drug

Clover Biopharmaceuticals Administers First Dose of COVID-19 Vaccine SCB-2019 in Zhejiang

Fineline Cube Feb 14, 2023

China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced the first jab of its COVID-19 vaccine...

Posts pagination

1 … 615 616 617 … 718

Recent updates

  • Ascletis Pharma Initiates US Phase 1 Study of ASC36 Oral Tablets – An Oral Amylin Receptor Agonist for Obesity, Advancing a Dual‑Format Program Alongside Its Once‑Monthly Injectable
  • Guangzhou Baiyunshan Pharma Wins Registration and Marketing Approval in Macau for Its Freeze‑Dried Rabies Vaccine (Vero Cells) – Joining a Highly Concentrated Supplier Landscape
  • Alebund Pharma Secures US FDA Clinical Trial Approval for AP308 – A First‑in‑Class Recombinant IgA Protease Aimed at a Functional Cure for IgA Nephropathy
  • InnoCare Pharma Secures NMPA Clinical Trial Approval for ICP‑B381 – First Bispecific PSMA/STEAP1 ADC From Its Proprietary Platform, Targeting Prostate Cancer and Other Solid Tumors
  • Accropeutics’ Oral TYK2 Inhibitor AC-201 Cleared for Vitiligo Phase II/III
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Ascletis Pharma Initiates US Phase 1 Study of ASC36 Oral Tablets – An Oral Amylin Receptor Agonist for Obesity, Advancing a Dual‑Format Program Alongside Its Once‑Monthly Injectable

Company Drug

Guangzhou Baiyunshan Pharma Wins Registration and Marketing Approval in Macau for Its Freeze‑Dried Rabies Vaccine (Vero Cells) – Joining a Highly Concentrated Supplier Landscape

Company Drug

Alebund Pharma Secures US FDA Clinical Trial Approval for AP308 – A First‑in‑Class Recombinant IgA Protease Aimed at a Functional Cure for IgA Nephropathy

Company Drug

InnoCare Pharma Secures NMPA Clinical Trial Approval for ICP‑B381 – First Bispecific PSMA/STEAP1 ADC From Its Proprietary Platform, Targeting Prostate Cancer and Other Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.